At this Breakfast Meeting, Dr. Ataru Igarashi, one of the few HTA professionals in Japan, will join us to explain what HTA is, how it evaluates the value of medicine, and how HTA outcomes can be reflected in policies, with examples from recent HTA use cases.


Please note that this event will be held only in Japanese

■Speraker：
Dr. Ataru Igarashi
(Assistant Professor at The University of Tokyo’s Graduate School of Pharmaceutical Sciences)
■Date & Time:
Thursday, Jun 2, 2016   8:00-9:15am (Doors open 7:45am)
■Venue：
　EGG JAPAN
(10th floor, Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo)
■Participation fee:
General: 2,500 JPN Yen
Students: 1,500 JPN Yen for students (Student ID required)
Individual supporting members: Free

■Summary:
There has recently been more and more movement toward the introduction of Health Technology Assessments (HTA) to the health care policy making process in light of increased healthcare costs. In Japan, a trial introduction of cost-effectiveness evaluations within the drug and medical device approval process was started following the FY2016 Revision of Medical Fee.

In order to construct a sustainable health care system that meets global standards, Japan must utilize the limited resources available to it as efficiently and effectively as possible and maximize the value attainable from healthcare services. At the next Breakfast Meeting, Dr. Ataru Igarashi, one of the few HTA professionals in Japan, will join us to explain what HTA is, how it evaluates the value of medicine, and how HTA outcomes can be reflected in policies, with examples from recent HTA use cases.

■Keywords:
Pharmacoeconomics, Health Economics Evaluation, Cost-effectiveness Evaluation, QALY (Quality Adjusted Life years), QOL (Quality of Life)

■About Dr. Igarashi:
Dr. Igarashi received his Ph.D. (Pharmacoeconomics/Pharmaceutical Economics) from the Endowed Laboratory of Drug Policy and Management in the Graduate School of Pharmaceutical Sciences of the University of Tokyo (2008). He is Co-President of the Health Outcome Research Institute (2010 – Present). He specializes in biostatistics, health economics, and pharmacoeconomics.

■ Reference book:
・‘What is Pharmacoeconomics?’ (Authors: Ataru Igarashi, Mari Sato)

http://goo.gl/pnXuCD
・Nikkei Medical Online Series ‘I can’t quite understand what Pharmacoeconomics is’ by Ataru Igarashi”
http://medical.nikkeibp.co.jp/inc/all/series/yakuzaikeizai/


*Registration will close at 23:59 pm on May 22. Participants will be selected by lot and will be informed of the result by the end of May 24. We appreciate your understanding.
**Please inform us if you would like to cancel by 17:00, May 30. If you cancel after this, participation fee might incur.

Registration deadline: 2016-05-22

Exhibition date：2016-06-02